Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,168,519 papers from all fields of science
Search
Sign In
Create Free Account
ALT 711
Known as:
711 alt
, ALT-711
, ALT711
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
alagebrium
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Alagebrium targets the miR-27b/TSP-1 signaling pathway to rescue Nε-carboxymethyl-lysine-induced endothelial dysfunction.
Yihong Chen
,
Wenhao Niu
,
+4 authors
C. Liang
American journal of translational research
2019
Corpus ID: 108293946
Nε-carboxymethyl-lysine (CML), a major isoform of advanced glycation end products (AGEs), plays a crucial role in the functional…
Expand
2014
2014
AGEs breaking and antioxidant treatment improves endothelium-dependent dilation without effect on flow-mediated remodeling of resistance arteries in old Zucker diabetic rats
M. L. Freidja
,
E. Vessières
,
+5 authors
D. Henrion
Cardiovascular Diabetology
2014
Corpus ID: 13049710
BackgroundA chronic increase in blood flow in resistance arteries is associated with increased lumen diameter (outward remodeling…
Expand
2014
2014
Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats
Bing Zhang
,
K. He
,
+5 authors
Lili Wang
Hypertension Research
2014
Corpus ID: 205148900
Combining drugs with complementary mechanisms of action may contribute to improved hypertension control in diabetic patients…
Expand
2011
2011
The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
M. Krautwald
,
Dale Leech
,
+5 authors
G. Münch
Rejuvenation Research
2011
Corpus ID: 24847280
Advanced glycation end products (AGEs) are involved in age-related diseases, including the complications of diabetes and chronic…
Expand
2010
2010
Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia
Bin Shen
,
Francesco Vetri
,
Lizhen Mao
,
Haoliang Xu
,
C. Paisansathan
,
D. Pelligrino
Brain Research
2010
Corpus ID: 23458801
2009
2009
Letter by Hartog et al. regarding article, "Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines".
J. Hartog
,
S. Willemsen
,
A. Voors
Circulation
2009
Corpus ID: 207722119
We thank Dr Hartog and colleagues for their interest in our study1 and agree with their conclusion that other advanced glycation…
Expand
2009
2009
The Thiamine Analogue and Advanced Glycation Endproducts Crosslink Breaker ALT-711 does not Interfere with Transketolase Activity
M. Krautwald
,
P. Maxwell
,
Grant Stuchbury
,
J. Holtum
,
J. Burnell
,
G. Münch
2009
Corpus ID: 577117
The enzyme transketolase (sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glycolaldehydetransferase, EC 2.2.1.1) is…
Expand
Review
2004
Review
2004
Crosslink breakers: a new approach to cardiovascular therapy
D. Sušić
,
J. Varagić
,
Jwari Ahn
,
E. Frohlich
Current Opinion in Cardiology
2004
Corpus ID: 36107991
Purpose of review Advanced glycation end-products accumulate on body proteins with aging, and their formation is greatly enhanced…
Expand
Review
2001
Review
2001
ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure
S. Doggrell
Expert Opinion on Investigational Drugs
2001
Corpus ID: 6187590
Vascular and/or myocardial stiffness is a major problem in ageing, diabetes, hypertension and heart failure. The development of…
Expand
2000
2000
Improvement by aminoguanidine of insulin secretion from pancreatic islets grafted to syngeneic diabetic rats.
S. Hiramatsu
,
K. Inoue
,
Y. Tajirl
,
V. Grill
Biochemical Pharmacology
2000
Corpus ID: 849512
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE